CR9663A - Heterociclos de 1,4-dihidropiridina-condensados, procesos para preparar los mismos, uso y composiciones que los contienen - Google Patents

Heterociclos de 1,4-dihidropiridina-condensados, procesos para preparar los mismos, uso y composiciones que los contienen

Info

Publication number
CR9663A
CR9663A CR9663A CR9663A CR9663A CR 9663 A CR9663 A CR 9663A CR 9663 A CR9663 A CR 9663A CR 9663 A CR9663 A CR 9663A CR 9663 A CR9663 A CR 9663A
Authority
CR
Costa Rica
Prior art keywords
processes
condensed
compositions containing
dihydropiridine
heterocicles
Prior art date
Application number
CR9663A
Other languages
English (en)
Inventor
Jacques Mauger
Anil Nair
Nina Ma
Kirsten Bjergarde
Bruno Filoche-Romme
Odile Angouillant-Boniface
Serge Mignani
Cecile Combeau
Jean-Christophe Carry
Francois Clerc
Herve Minoux
Laurent Schio
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Publication of CR9663A publication Critical patent/CR9663A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

Heterociclos de 1,4-dihidropiridina-condensados, procesos para preparar los mismos, uso y composiciones que los contienen. La invencion se refiere a heterociclos dihidropiridina-condensados sustituidos utiles para el tratamiento de enfermedad de cancer, especialmente para prevenir la division de celulas cancerigenas. Estos compuestos actuan como inhibidores de Aurora A y /o B quinasas.
CR9663A 2005-07-20 2008-01-15 Heterociclos de 1,4-dihidropiridina-condensados, procesos para preparar los mismos, uso y composiciones que los contienen CR9663A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP05291558A EP1746097B1 (en) 2005-07-20 2005-07-20 1,4-dihydropyridine-fused heterocycles, process for preparing the same, use and compositions containing them

Publications (1)

Publication Number Publication Date
CR9663A true CR9663A (es) 2008-02-21

Family

ID=35510894

Family Applications (1)

Application Number Title Priority Date Filing Date
CR9663A CR9663A (es) 2005-07-20 2008-01-15 Heterociclos de 1,4-dihidropiridina-condensados, procesos para preparar los mismos, uso y composiciones que los contienen

Country Status (37)

Country Link
US (1) US8163768B2 (es)
EP (2) EP1746097B1 (es)
JP (2) JP2009501778A (es)
KR (1) KR101286796B1 (es)
CN (1) CN101243087B (es)
AR (1) AR054845A1 (es)
AT (2) ATE455115T1 (es)
AU (1) AU2006273692B8 (es)
BR (1) BRPI0614002A2 (es)
CA (1) CA2615700C (es)
CR (1) CR9663A (es)
CY (1) CY1109964T1 (es)
DE (1) DE602005018911D1 (es)
DK (1) DK1746097T3 (es)
DO (1) DOP2006000175A (es)
EA (1) EA016815B1 (es)
EC (1) ECSP078062A (es)
ES (1) ES2339676T3 (es)
HN (1) HN2008000088A (es)
HR (1) HRP20100195T1 (es)
IL (1) IL188861A0 (es)
MA (1) MA29634B1 (es)
MX (1) MX2008000902A (es)
MY (1) MY148617A (es)
NO (1) NO20080831L (es)
NZ (1) NZ592766A (es)
PE (2) PE20070212A1 (es)
PL (1) PL1746097T3 (es)
PT (1) PT1746097E (es)
RS (1) RS51351B (es)
SI (1) SI1746097T1 (es)
TN (1) TNSN08020A1 (es)
TW (1) TWI386411B (es)
UA (1) UA98928C2 (es)
UY (1) UY29685A1 (es)
WO (1) WO2007012972A2 (es)
ZA (1) ZA200800542B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2945535B1 (fr) 2009-05-18 2011-06-10 Sanofi Aventis Compose anticancereux et composition pharmaceutique le contenant
FR2967413A1 (fr) * 2010-11-17 2012-05-18 Sanofi Aventis Compose 8-oxo-9-[3-(1h-benzimidazol-2-yloxy)-phenyl]-4,5,6,7,8,9-hexahydro-2h-pyrrolo[3,4-b]quinoline-3-carboxylate d'ethyle, sel, forme cristalline, co-cristal, formulation, procedes de preparation, application a titre de medicaments, compositions pharmaceutiques et nouvelle utilisation notamment comme inhibiteur des kinases aurora.
US9340537B2 (en) 2012-05-15 2016-05-17 Novatis Ag Benzamide derivatives for inhibiting the activity of ABL1, ABL2 and BCR-ABL1
EA201492005A1 (ru) 2012-05-15 2015-04-30 Новартис Аг Бензамидные производные для ингибирования активности abl1, abl2 и bcr-abl1
CN104334529B (zh) 2012-05-15 2017-03-15 诺华股份有限公司 用于抑制abl1、abl2和bcr‑abl1的活性的化合物和组合物
JP6078639B2 (ja) 2012-05-15 2017-02-08 ノバルティス アーゲー Ａｂｌ１、ａｂｌ２およびｂｃｒ−ａｂｌ１の活性を阻害するためのベンズアミド誘導体
PT2909204T (pt) 2012-10-12 2019-03-21 Dana Farber Cancer Inst Inc Inibidores de gsk3 e métodos de utilização dos mesmos
CA2968884A1 (en) 2014-12-10 2016-06-16 Massachusetts Institute Of Technology Fused 1,3-azole derivatives useful for the treatment of proliferative diseases
EP4212532A3 (en) 2015-04-30 2023-09-27 Memorial Sloan Kettering Cancer Center Mitragynine analogs and uses thereof
RU2619932C1 (ru) * 2015-11-25 2017-05-22 федеральное государственное бюджетное образовательное учреждение высшего образования "Воронежский государственный университет" (ФГБОУ ВО "ВГУ") ЗАМЕЩЕННЫЕ ПИРАЗОЛО[1,5-а]ПИРИДО[3,4-е]ПИРИМИДИНЫ И ИХ ИСПОЛЬЗОВАНИЕ В КАЧЕСТВЕ ИНГИБИТОРОВ ПРОТЕИНКИНАЗ
WO2017124087A1 (en) 2016-01-15 2017-07-20 Memorial Sloan-Kettering Cancer Center Anti-parasitic compounds and uses thereof
CN109071456A (zh) 2016-02-16 2018-12-21 麻省理工学院 作为myc调节剂的max结合剂及其用途
WO2018187630A1 (en) 2017-04-05 2018-10-11 The Broad Institute, Inc. Tricyclic compounds as glycogen synthase kinase 3 (gsk3) inhibitors and uses thereof
CA3056305A1 (en) 2017-05-12 2018-11-15 Rti International Diarylureas as cb1 allosteric modulators

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA9811178B (en) * 1997-12-13 2000-06-07 Bristol Myers Squibb Co Use of pyrazolo (3,4-b) pyridine as cyclin dependent kinase inhibitors.
MXPA02005016A (es) 1999-11-19 2003-01-28 Abbott Lab Abridores de canal de potasio de dihidropirimidina triciclica.
ATE268331T1 (de) 2000-03-03 2004-06-15 Abbott Lab Tricyclische dihydropyrazolone und tricyclische dihydroisoaxazolone als kaliumkanalöffner
US6538004B2 (en) 2000-03-03 2003-03-25 Abbott Laboratories Tricyclic dihydropyrazolone and tricyclic dihydroisoxazolone potassium channel openers
CN1630656A (zh) 2001-02-02 2005-06-22 三菱制药株式会社 二氢吡唑并吡啶化合物及其制药用途
FR2823854A1 (fr) 2001-04-18 2002-10-25 Centre Nat Rech Scient Nouveau procede de criblage d'inhibiteurs de la liaison entre la proteine oxyde nitrique synthase neuronale et la proteine inhibitrice de l'oxyde nitrique synthase neuronale
FR2825091B1 (fr) * 2001-05-23 2003-07-04 Servier Lab Nouveaux derives tricycliques de dihydro-quinnoleines, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US7037902B2 (en) * 2002-07-03 2006-05-02 Receptron, Inc. Affinity small molecules for the EPO receptor
SE0301371D0 (sv) 2003-05-09 2003-05-09 Astrazeneca Ab New Compounds
WO2005016245A2 (en) * 2003-06-13 2005-02-24 Zentaris Gmbh Compounds having inhibitive activity of phosphatidylinositol 3-kinase and methods of use thereof

Also Published As

Publication number Publication date
ES2339676T3 (es) 2010-05-24
JP2013063987A (ja) 2013-04-11
ATE521611T1 (de) 2011-09-15
CY1109964T1 (el) 2014-09-10
TWI386411B (zh) 2013-02-21
EP1746097A1 (en) 2007-01-24
US8163768B2 (en) 2012-04-24
BRPI0614002A2 (pt) 2011-03-01
SI1746097T1 (sl) 2010-05-31
PL1746097T3 (pl) 2010-06-30
AR054845A1 (es) 2007-07-18
AU2006273692B2 (en) 2012-11-22
JP2009501778A (ja) 2009-01-22
NO20080831L (no) 2008-04-03
ZA200800542B (en) 2010-02-24
MY148617A (en) 2013-05-15
IL188861A0 (en) 2008-04-13
ECSP078062A (es) 2008-01-23
TNSN08020A1 (en) 2009-07-14
DOP2006000175A (es) 2007-03-31
DE602005018911D1 (de) 2010-03-04
EP1910366A2 (en) 2008-04-16
MA29634B1 (fr) 2008-07-01
EA200800374A1 (ru) 2008-08-29
PE20100718A1 (es) 2010-10-20
NZ592766A (en) 2012-12-21
ATE455115T1 (de) 2010-01-15
CA2615700A1 (en) 2007-02-01
DK1746097T3 (da) 2010-05-25
HRP20100195T1 (hr) 2010-05-31
AU2006273692A1 (en) 2007-02-01
AU2006273692A8 (en) 2012-12-13
WO2007012972A2 (en) 2007-02-01
UA98928C2 (ru) 2012-07-10
CA2615700C (en) 2013-06-18
CN101243087A (zh) 2008-08-13
KR20080026658A (ko) 2008-03-25
CN101243087B (zh) 2013-07-24
AU2006273692B8 (en) 2012-12-13
HN2008000088A (es) 2011-05-31
US20080261969A1 (en) 2008-10-23
RS51351B (sr) 2011-02-28
KR101286796B1 (ko) 2013-07-17
EP1746097B1 (en) 2010-01-13
EP1910366B1 (en) 2011-08-24
TW200740812A (en) 2007-11-01
WO2007012972A3 (en) 2007-04-05
PE20070212A1 (es) 2007-03-21
PT1746097E (pt) 2010-04-15
EA016815B1 (ru) 2012-07-30
MX2008000902A (es) 2008-03-26
UY29685A1 (es) 2007-02-28

Similar Documents

Publication Publication Date Title
CR9663A (es) Heterociclos de 1,4-dihidropiridina-condensados, procesos para preparar los mismos, uso y composiciones que los contienen
CU23778B7 (es) Pirrolopirazoles, inhibidores potentes de quinasa
CL2011003082A1 (es) Compuestos derivados de [1,2,4]triazolo[1,5-a]piridina, inhibidores de jak2 o fak; composiciones farmaceuticas que los comprenden; y su uso para el tratamiento de una enfermedad hiperproliferativa.
CL2008001743A1 (es) Uso de un compuesto derivado de quinazolina para tratar el cancer; uso del compuesto y de otro compuesto antineoplasico; compuestos derivados de quinazolina; y composicion farmaceutica que los comprende.
BRPI0607455A2 (pt) composto, processo para a preparação do mesmo, uso de um composto, e composição farmacêutica
ECSP088450A (es) Derivados de pirimidina 4-(3-aminopirazol) para uso como inhibidores de tirosina quinasa en el tratamiento de cáncer
UY30748A1 (es) Compuesto0s novedosos
UY28708A1 (es) Heterociclos sustituídos y usos de los mismos
GT200900027A (es) Compuestos organicos
GT200800187A (es) Compuestos de tetrahidropiridotienopirimidina y procedimientos de uso de los mismos
CU23464B7 (es) (1,8)naftidirin-2-onas y compuestos relacionados para el tratamiento de la esquizofrenia
ATE479687T1 (de) Kinaseinhibitoren
UY29781A1 (es) Compuestos diazaspiro sustituidos, sales farmacéuticamente aceptables, composiciones farmacéuticas que contienen los compuestos o sales, métodos de preparación y usos
ECSP088145A (es) Derivados bicíclicos como inhibidores de la cinasa p38
CR20110028A (es) Derivados de pirimidina como inhibidores de cinasa
BRPI0510177B8 (pt) composto, composição farmacêutica e uso do mesmo
GT201000061A (es) Derivados de uracilo o timina para el tratamiento de hepatitis c
CR9786A (es) Compuestos de bencimidazol-tiofeno
CU20090064A7 (es) Nuevos derivados de benzamida como antagonistas de la bradiquinina
UY29414A1 (es) Derivados de pirimidina para el tratamiento de trastornos hiperproliferativos
MXPA04002042A (es) Compuestos de bencimidazol sustituidos y su uso para el tratamiento del cancer.
CL2004000979A1 (es) Nonapeptidos acilados tipo lysobacitina, composicion que los contiene metodo de preparacion, util como bactericida.
UY29070A1 (es) Enantiómeros de heterocíclicos fusionados y sus usos
UY27394A1 (es) Pedidos con actividad anti- angiogéna.
GT200700006A (es) Heterociclos de 1,4-dihidropiridina-condensados, procesos para preparar los mismos, uso y composiciones que los contienen